Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

NCT01141257 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Angiocal® (PRS-050-PEG40)

Sponsor

Pieris Pharmaceuticals GmbH

Collaborators

[object Object]